VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Given Average Recommendation of “Reduce” by Analysts

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) has been assigned an average rating of “Reduce” from the five ratings firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have given a hold recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $0.95.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of VistaGen Therapeutics in a report on Wednesday, June 3rd.

Hedge Funds Weigh In On VistaGen Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Virtu Financial LLC bought a new stake in shares of VistaGen Therapeutics in the 4th quarter worth about $25,000. Cubist Systematic Strategies LLC bought a new position in shares of VistaGen Therapeutics in the 1st quarter valued at about $25,000. Schonfeld Strategic Advisors LLC bought a new position in shares of VistaGen Therapeutics in the 3rd quarter valued at about $39,000. Seven Fleet Capital Management LP purchased a new position in VistaGen Therapeutics in the fourth quarter worth about $42,000. Finally, Tudor Investment Corp ET AL purchased a new position in VistaGen Therapeutics in the fourth quarter worth about $50,000. 78.39% of the stock is owned by hedge funds and other institutional investors.

VistaGen Therapeutics Stock Performance

NASDAQ:VTGN opened at $0.25 on Monday. The business’s 50-day moving average is $0.30 and its 200 day moving average is $0.49. VistaGen Therapeutics has a 12 month low of $0.20 and a 12 month high of $5.14. The company has a market capitalization of $11.22 million, a P/E ratio of -0.15 and a beta of 0.41.

VistaGen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.06. The business had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $0.50 million. VistaGen Therapeutics had a negative return on equity of 152.59% and a negative net margin of 2,702.64%. On average, research analysts forecast that VistaGen Therapeutics will post -1.32 earnings per share for the current year.

About VistaGen Therapeutics

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.